Kyungdong Pharm경동제약

Kyungdong Pharm is profitable on a trailing basis after a weak 2023, but its shares have fallen about 16% over the past year.

Kyungdong Pharm, a Seoul-listed drugmaker whose sales are about 95% pharmaceuticals, reported trailing revenue of ₩201B and operating income of ₩11.8B for the twelve months to H1 2026. Its share price was ₩4,900 on 23 October 2026, near the lower half of its 52-week range of ₩4,700 to ₩6,270, and its market value is about ₩151B. The data does not include analyst ratings or forecasts for the company.

What stands out

• Trailing operating margin is 5.9% and net margin is 8.9%, up from a 2023 operating loss of ₩25B, though 2025 operating margin was 3.9%.
• Net income is well above operating income in the trailing figures, so non-operating items likely contributed; the data does not break this down.
• Balance sheet looks moderate: liabilities are 32.9% of equity, borrowings of ₩25.4B exceed cash of ₩13.1B, and trailing free cash flow was ₩4.6B.
• Valuation metrics show a P/E of 8.5, P/B of 0.7 and a dividend yield of 6.1%, while the DCF fair value in the data is ₩1,625 with a bull case of ₩5,256.
• Foreign ownership fell slightly from 2.0% to 1.9% over 60 days, and 20-day flows were net foreign selling of about ₩176M against net retail buying of about ₩158M.

What to watch

• Next quarterly and annual results, since the trailing figures rely on the H1 2026 half-year report and the next filing will show whether margins hold.
• Ongoing shareholder filings, including the amended largest-shareholder change filed in August 2026 and recent 5%+ holding reports.
• The company's reliance on domestic sales of a small product range; the data names no specific pipeline or regulatory catalysts.